Merck & Co., Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax
Merck & Co., Inc. (MRK) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax of -$8.00 million for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-07.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax · last filed 2013-11-07
- Merck & Co., Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2013-09-30 was -$8.00M.
- Merck & Co., Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2013-06-30 was -$4.00M.
- Merck & Co., Inc. oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2013-03-31 was $12.00M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 9 month |
|---|---|---|---|
| 2013-09-30 | -$8.00M 10-Q · filed 2013-11-07 | -$12.00M derived: sum of 2 quarters · filed 2013-11-07 | -$16.00M 10-Q · filed 2013-11-07 |
| 2013-06-30 | -$4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $8.00M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $12.00M 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |